SP140
Overview
SP140 encodes a lymphoid-restricted homolog of the nuclear body protein SP100. It contains a bromodomain and a PHD finger, suggesting roles in chromatin regulation and transcriptional control. SP140 has been identified as a candidate tumor suppressor in multiple myeloma, where missense, frameshift, and splice-site mutations occur with accompanying loss of heterozygosity.
Alterations observed in the corpus
- Missense, frameshift, and splice-site alterations in 8 patients in a multiple myeloma (MM) genomic cohort, with 2 cases showing LOH; classified as a candidate tumor suppressor due to lymphoid-restricted expression pattern (SP100 homolog) PMID:24434212
Cancer types (linked)
- MM: recurrently mutated (8 patients) with LOH in 2 cases in a comprehensive MM genomic analysis PMID:24434212
Co-occurrence and mutual exclusivity
- No specific co-mutation exclusivity relationships reported in this corpus.
Therapeutic relevance
- Bromodomain-containing protein; bromodomain inhibitors may be indirectly relevant but no direct targeting reported in this corpus.
Open questions
- Functional validation of SP140 as a tumor suppressor in MM is lacking; the mechanism by which SP140 loss promotes myeloma pathogenesis is undefined.
Sources
This page was processed by entity-page-writer on 2026-05-09.